Information for medical professionals from market surveillance of medicinal products
Pharmacovigilance in the spotlight
Learning from adverse reaction reports – cases from pharmacovigilance
The purpose of this new section is to use real-life case reports from Switzerland as a reminder of possible side effects that professionals should be aware of in day-to-day clinical practice. The only way to protect patients against undesirable effects is to take account of and report medicinal product risks.
26.11.2022
Fluoroquinolones | moxifloxacin | iprofloxacin | levofloxacin | tendon rupture | Achilles tendon
21.11.2022
Hyperthyroidism | amiodarone | thyroiditis | iodine level
Swissmedic Vigilance-News
Topical aspects of medicinal product risk assessment
Twice a year, the Safety of Medicines Division reports on current topics relating to adverse reaction surveillance and the evaluation of safety signals. Swissmedic's "Vigilance News" appears twice a year as an online resource.
22.11.2022
In this edition:
- Reports of urticaria after booster vaccination with Spikevax
- Contrast-induced neurotoxicity
- Swiss Haemovigilance System: Regulatory aspects and transfusion reactions
- Statistical Review 2021: Pharmacovigilance for human medicinal products, vaccinovigilance, vigilance for veterinary medicinal products
23.05.2022
In this edition:
COVID-19 immunisation:
- Modification of the Information for healthcare professionals since authorisation
- Myocarditis, thromboembolic events, multiple sclerosis
- Persistent headache
- Methods of signal detection / ”Observed versus expected” analyses
29.11.2021
In this edition:
COVID-19 immunisation:
- Myocarditis/pericarditis: Case reports received by Swissmedic
- Menstrual disorders – facts, possible causes, unanswered questions
- Recent study findings and recommendations
for vaccination of pregnant women
- International cooperation
in the area of pharmacovigilance
29.06.2021
In this edition:
- COVID-19 vaccines: reporting suspected side effects correctly
- Case report “COVID arm”
- AEFI after immunisation with COVID-19 vaccines: Herpes zoster, neuralgic amyotrophy, immune thrombocytopenia
